Huntington National Bank’s aTyr Pharma ATYR Stock Holding History

Huntington National Bank’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-700	Closed	-$3.55K	–	4214
2025 Q2	$3.55K	Buy	+700	New	+$2.75K	﹤0.01%	2093

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Huntington National Bank's ATYR Position: Q3 2025 in Review

Huntington National Bank sold out of aTyr Pharma (ATYR) in Q3 2025, closing a stake of 700 shares — an estimated $3.55K sold.

Huntington National Bank first reported a position in ATYR in Q2 2025 and held it in 1 quarter. The position peaked at $3.55K in Q2 2025. 103 funds tracked by Wall St. Rank hold ATYR as of Q3 2025.

Huntington National Bank reported no remaining aTyr Pharma position as of Q3 2025 after selling out during the quarter.
Huntington National Bank sold 700 aTyr Pharma shares in Q3 2025, an estimated $3.55K.
Huntington National Bank first reported a position in aTyr Pharma in Q2 2025 and held it in 1 quarter.
Huntington National Bank's aTyr Pharma position peaked at $3.55K in Q2 2025.
103 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2025.

Based on Huntington National Bank's 13F filing for Q3 2025, filed 12 Nov 2025.